Abstract
This brand new report investigates the global market for therapeutic
monoclonal antibodies. While the pharmaceutical industry as a whole is
suffering from single digit growth, thinner pipelines than before and pressure
from an ever-aggressive generics industry, the segment of monoclonal
antibodies therapeutics is thriving and growing at a double-digit rate.
Therapeutic Monoclonal Antibodies 2008-2023 shows how monoclonal antibodies
are a leading product of biotechnology, being increasingly used in therapy.
Currently, monoclonal antibodies are playing an important role in the
treatment of cancer, autoimmune and inflammatory disorders.
Therapeutic monoclonal antibodies boast one of the most active and promising
pipelines in the pharmaceutical industry.
Ten years ago, there were only two monoclonal antibody drugs on the world
market, now there are 21 FDA approved therapies - including eight blockbuster
drugs. In 2007, the market was worth $21.9bn, but what will it be in 5 years
time? This report will tell you and tell you today. Visiongain believes that
some of the greatest opportunities ever available for biopharmaceutical
companies are now there to be seized, with important sales, licensing
agreements and collaborative partnerships from the present onwards in
monoclonal antibodies and other biologicals.
Our new Therapeutic Monoclonal Antibodies 2008-2023 report examines the market
for monoclonal antibodies critically, through comprehensive primary and
secondary research. In addition to consultation with experts in industry -
including full interview transcripts - this research involved a detailed study
of relevant documents, industrial reports and current developments.
Visiongain discusses the monoclonal antibody market in the context of the
biotechnological platforms and therapeutic areas. Importantly, visiongain
applied techniques such as financial forecasting and analysis of drivers and
restraints. The result is a comprehensive market-based report with detailed
analyses and informed opinion. In particular, Therapeutic Monoclonal
Antibodies 2008-2023 concentrates on the following essential aspects of the
monoclonal antibodies sector:
- Technologies that drive the MAb sector
- Therapy areas that drive the MAb sector
- Sales forecasts of the global therapeutic MAb market from 2008-2023 -
including those of principal market segments, both by disease area and
technology
- Sales forecasts for leading products worldwide in this sector
- Sales forecasts for therapeutic MAb sales in leading national markets,
including China and India
- Key industrial players in the therapeutic monoclonal antibody sector -
both established and emerging - including partnerships
- Drivers and opportunities in the MAb sector
- Restraints and threats in the MAb sector
- Assessments of relevant business models, technological solutions and
associated issues
- Coverage of future trends in MAbs, especially pipeline developments
Insight from interviews with relevant experts Why you should buy this report:
- To receive a comprehensive analysis of the prospects for the therapeutic
monoclonal antibodies industry from 2008-2023, including sales forecasts,
major growth areas and pipeline products
- To discover predicted revenues, growth rates and other key metrics in the
therapeutic monoclonal antibodies market from 2008-2023, especially for
leading brands
- To determine the forces that influence the therapeutic monoclonal
antibodies market: Drivers and restraints on market Competition Strengths,
weaknesses, opportunities and threats.
- To find out where the therapeutic monoclonal antibodies market is heading
from 2008 onwards - both technologically and commercially
| 
View Cart
